

- 2 -

In the Claims

Please cancel claims 6 and 16.

Please amend claim 1.

Please re-write the claims as follows:

1. (Currently Amended) A method for treating a subject having an inflammatory joint disorder comprising

administering to a subject in need of such treatment a therapeutically effective amount of a cadherin-11 inhibitory agent

wherein the cadherin-11 inhibitory agent is an antibody to cadherin-11 that inhibits binding of cadherin-11 to a cadherin-11 counter-receptor that is a cadherin-11.

2. (Cancelled)

3. (Original) The method of claim 1, wherein the inflammatory joint disorder is an autoimmune disease.

4. (Cancelled)

5. (Original) The method of claim 1, wherein the cadherin-11 inhibitory agent is administered locally to a synovium of the subject.

6. - 49. (Cancelled)

50. (Previously Presented) The method of claim 1, wherein the inflammatory joint disorder is chronic synovitis.

51. (Previously Presented) The method of claim 3, wherein the autoimmune disease is rheumatoid arthritis.

- 3 -

52. (Previously Presented) The method of claim 1, wherein cadherin-11 and the cadherin-11 counter-receptor are expressed by separate cells.

53. (Previously Presented) The method of claim 1, wherein cadherin-11 is expressed by a cell selected from the group consisting of a type A synoviocyte, a type B synoviocyte, a synovial derived fibroblast, a synovial membrane lining cell, an osteoblast, a cartilage-derived cell and an invasive pannus-derived cell.

54. (Previously Presented) The method of claim 1, wherein the cadherin-11 counter-receptor is expressed by a synoviocyte.

55. – 56. (Cancelled)

57. (Previously Presented) The method of claim 1, wherein administering is administering systemically.

58. (Cancelled)

59. (Previously Presented) The method of claim 1, wherein the cadherin-11 counter-receptor is expressed by a type B synoviocyte.

60. (Previously Presented) The method of claim 1, wherein the cadherin-11 counter-receptor is expressed by an invasive pannus-derived cell.